PMID- 27200590
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160610
LR  - 20160521
IS  - 1524-4733 (Electronic)
IS  - 1098-3015 (Linking)
VI  - 17
IP  - 7
DP  - 2014 Nov
TI  - The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body 
      Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 
      Diabetes Mellitus (T2DM).
PG  - A334
LID - S1098-3015(14)02569-8 [pii]
LID - 10.1016/j.jval.2014.08.639 [doi]
FAU - Diels, J
AU  - Diels J
AD  - Janssen Research & Development, Beerse, Belgium.
FAU - Angermund, R
AU  - Angermund R
AD  - Janssen-Cilag Germany, Mainz, Germany.
FAU - Schroeder, M
AU  - Schroeder M
AD  - Janssen-Cilag UK, High Wycombe, UK.
FAU - Worbes-Cerezo, M
AU  - Worbes-Cerezo M
AD  - Janssen-Cilag UK, High Wycombe, UK.
FAU - Thompson, G
AU  - Thompson G
AD  - Janssen-Cilag UK, High Wycombe, UK.
LA  - eng
PT  - Journal Article
DEP - 20141026
PL  - United States
TA  - Value Health
JT  - Value in health : the journal of the International Society for Pharmacoeconomics 
      and Outcomes Research
JID - 100883818
EDAT- 2014/11/01 00:00
MHDA- 2014/11/01 00:01
CRDT- 2016/05/21 06:00
PHST- 2016/05/21 06:00 [entrez]
PHST- 2014/11/01 00:00 [pubmed]
PHST- 2014/11/01 00:01 [medline]
AID - S1098-3015(14)02569-8 [pii]
AID - 10.1016/j.jval.2014.08.639 [doi]
PST - ppublish
SO  - Value Health. 2014 Nov;17(7):A334. doi: 10.1016/j.jval.2014.08.639. Epub 2014 Oct 
      26.